Spesolimab (Spevigo®): A Comprehensive Monograph on the First-in-Class Interleukin-36 Receptor Antagonist for Generalized Pustular Psoriasis

Section 1: Introduction to Spesolimab (Spevigo®)

1.1 The Clinical Challenge of Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis (GPP) is a rare, severe, and chronic autoinflammatory skin disease that is both genetically and clinically distinct from the more common plaque psoriasis.[1] The condition is characterized by the sudden and widespread eruption of painful, sterile pustules that form on an erythematous base, often covering large areas of the body.[3] These flares are frequently accompanied by systemic inflammation, manifesting as fever, chills, intense pruritus, debilitating fatigue, myalgia, and joint pain.[3] The immunopathology of GPP is primarily driven by the dysregulation and hyperactivity of the interleukin-36 (IL-36) signaling pathway, a key component of the innate immune system.[6]

The clinical burden of GPP is profound. Flares are unpredictable and can be life-threatening, with the potential for severe complications including sepsis, hypocalcemia, cardiovascular failure, and multi-organ failure if left untreated.[2] This places an immense physical and emotional toll on patients and a significant burden on healthcare systems, often requiring hospitalization for management.[1] Prior to the advent of targeted therapies, the therapeutic landscape for GPP was fraught with challenges. There were no globally approved treatments developed specifically for GPP, forcing clinicians to rely on off-label use of systemic agents such as retinoids, cyclosporine, and methotrexate.[5] The evidence supporting these traditional therapies was limited, primarily derived from small case series and retrospective studies, and their use often resulted in unsatisfactory or only partial control of the disease, coupled with significant toxicity profiles.[11] This created a critical and long-standing unmet medical need for a safe, effective, and evidence-based therapy that could specifically target the underlying drivers of GPP.

1.2 Spesolimab (Spevigo®): A Paradigm Shift in GPP Management

Spesolimab, marketed under the brand name Spevigo®, represents a landmark therapeutic advance and a paradigm shift in the management of GPP.[14] It is a novel, humanized, selective monoclonal antibody that functions as an interleukin-36 receptor (IL-36R) antagonist.[14] As the first therapy to be specifically developed, rigorously studied in randomized controlled trials, and approved for the treatment of GPP, it directly targets the core of the disease's pathogenesis.[1]

The U.S. Food and Drug Administration (FDA) has recognized the novelty and significance of this agent by designating it a first-in-class medication.[14] This status underscores the profound innovation Spesolimab brings to a therapeutic area that previously lacked any approved targeted options, heralding a new era of precision medicine for patients suffering from this devastating condition.

1.3 Drug Identification and Properties

A comprehensive understanding of Spesolimab begins with its fundamental identifiers and physicochemical properties, which are essential for its classification and use in clinical, research, and regulatory contexts.

Table 1: Spesolimab (Spevigo®) - Key Drug Identifiers

Property	Details	Source(s)
Generic Name	Spesolimab; Spesolimab-sbzo	17
Brand Name	Spevigo®	14
DrugBank ID	DB15626	14
Type	Biotech, Protein-Based Therapy, Monoclonal Antibody (mAb)	14
CAS Number	2097104-58-8	14
Other Names / Synonyms	BI-655130; BI655130; Immunoglobulin G1, anti-(human interleukin 36 receptor)	17
Drug Class	Interleukin Inhibitor; Interleukin-36 Receptor Antagonist	17
Source	Humanized; Produced in Chinese Hamster Ovary (CHO) cells via recombinant DNA technology	17
Chemical Formula	C6480​H9988​N1736​O2012​S46​	14
Approx. Average Weight	145,500 - 146,000 Da	17

Section 2: Biochemical Profile and Pharmacodynamics

2.1 Molecular Characterization

Spesolimab is a precisely engineered biologic agent. It is classified as a humanized, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody.[17] The "humanized" designation indicates that the antibody, originally derived from a non-human species (mouse), has been genetically modified to replace most of its protein sequences with human ones, thereby reducing its potential for immunogenicity in patients.[23] Some sources further specify its structure as an IgG1k (kappa light chain) antibody.[23] The entire molecule is produced using advanced recombinant DNA technology within a well-established mammalian expression system, specifically Chinese Hamster Ovary (CHO) cells.[17] This controlled manufacturing process ensures a high degree of purity and consistency, which is critical for a therapeutic protein of this nature.

2.2 Mechanism of Action: Targeting the IL-36 Inflammatory Axis

The therapeutic efficacy of Spesolimab is rooted in its highly specific interruption of a key inflammatory pathway central to the pathophysiology of GPP.

The Central Role of the IL-36 Pathway in GPP

The scientific consensus identifies the dysregulation of the interleukin-36 (IL-36) signaling pathway as the principal driver of GPP.[6] The IL-36 family includes three pro-inflammatory cytokine members—IL-36α, IL-36β, and IL-36γ—which act as agonists.[17] These cytokines bind to the IL-36 receptor (IL-36R), a heterodimeric complex on the surface of various immune and epithelial cells. This receptor complex is composed of a primary binding subunit, IL-1RL2 (also known as IL-36R), and a co-receptor, IL-1RAcP, which is necessary for signal transduction.[17] The binding of IL-36 agonists to this receptor initiates a cascade of downstream intracellular signaling events, activating pro-inflammatory and pro-fibrotic pathways.[17] This leads to the upregulation and release of other inflammatory mediators, the robust recruitment of neutrophils into the epidermis, and the subsequent formation of the sterile pustules that are the clinical hallmark of GPP.[17]

The critical role of this pathway is powerfully substantiated by genetic evidence. A significant proportion of patients with GPP, particularly those with familial or early-onset disease, carry loss-of-function mutations in the IL36RN gene.[6] This gene encodes the natural IL-36 receptor antagonist (IL-36Ra), a protein that normally functions as a "brake" on the pathway by competing with the IL-36 agonists for receptor binding.[6] The absence or dysfunction of this natural antagonist leads to unchecked, pathological autoinflammation driven by unopposed IL-36 signaling.[6] Furthermore, mutations in other genes associated with the IL-36 axis, such as

CARD14, AP1S3, and SERPINA3, have also been identified in GPP patients, reinforcing the centrality of this pathway in the disease's pathogenesis.[6]

Spesolimab's Targeted Intervention

Spesolimab was rationally designed to act as a direct and potent antagonist of this aberrant signaling. Its mechanism of action is highly specific: it binds with high affinity to the human IL-36 receptor, specifically targeting the IL-1RL2 subunit.[17] This binding event physically obstructs the receptor's binding site, thereby preventing the cognate IL-36 ligands (IL-36α, IL-36β, and IL-36γ) from docking and activating the receptor complex.[17]

By blocking the initial step of ligand-receptor interaction, Spesolimab effectively shuts down the entire downstream inflammatory cascade before it can be amplified. This targeted inhibition leads to a rapid and sustained amelioration of inflammation.[17] Pharmacodynamic studies have confirmed that this blockade results in the normalization of key biomarkers associated with the innate immune system, the Th1/Th17 inflammatory axes, and neutrophil-related pathways, thereby calming the hyper-inflammatory state that characterizes a GPP flare.[23]

This precise mechanism of action provides a clear biological rationale for the broad efficacy of Spesolimab observed in clinical trials. The trials have consistently shown that the drug is effective in GPP patients regardless of their IL36RN gene mutation status.[6] This can be understood by considering the different ways the IL-36 pathway can become dysregulated. In patients with an

IL36RN mutation, the problem can be conceptualized as having "no brakes" on the inflammatory pathway, as the natural antagonist is absent or non-functional. In other patients, the issue may be an overexpression of the IL-36 ligands or mutations in other pathway components, which is akin to "pressing too hard on the accelerator".[6] Spesolimab's point of intervention is downstream of these initial defects. It does not attempt to replace the missing antagonist or reduce ligand levels; instead, it directly blocks the receptor that both of these scenarios ultimately act upon.[17] By blocking the receptor itself, Spesolimab is effective whether the underlying problem is a lack of inhibition or an excess of stimulation. This makes it a universally applicable targeted therapy for GPP that is driven by the IL-36 axis. This crucial aspect has significant clinical implications, as it obviates the need for genetic testing for

IL36RN status as a prerequisite for treatment, thereby simplifying and accelerating the decision-making process for clinicians managing this acute and severe disease.

Section 3: Comprehensive Pharmacokinetic Profile

The pharmacokinetic (PK) profile of Spesolimab—encompassing its absorption, distribution, metabolism, and elimination—provides the scientific foundation for its approved dosing regimens and distinct routes of administration for different clinical scenarios in GPP. Data have been derived from a series of Phase I studies in healthy volunteers as well as population PK modeling incorporating data from GPP patients.[28]

3.1 Absorption and Bioavailability

The route of administration profoundly influences the absorption kinetics and subsequent plasma concentration profile of Spesolimab.

• Intravenous (IV) Administration: As is characteristic of intravenously administered biologics, a 900 mg dose of Spesolimab results in immediate and 100% bioavailability.[31] This leads to a rapid attainment of maximum plasma concentration ( Cmax​), which is critical for acute interventions.[31]
• Subcutaneous (SC) Administration: Following subcutaneous injection, Spesolimab is absorbed much more slowly into the systemic circulation. The median time to reach maximum plasma concentration (Tmax​) is approximately 5.5 to 7 days.[29] The bioavailability of SC Spesolimab is incomplete and appears to be dose-dependent, increasing from an estimated 50% for a 150 mg dose to approximately 70% for a 300 mg dose.[29] This slower, more gradual absorption profile is better suited for maintenance therapy.

The distinct pharmacokinetic profiles of the two administration routes are not a limitation but rather a strategic advantage that allows the therapy to be precisely tailored to different clinical needs. A GPP flare is an acute, severe, and potentially life-threatening inflammatory storm that demands rapid and decisive therapeutic intervention.[3] The IV route, delivering a high initial

Cmax​ almost instantaneously, is ideally suited to quickly saturate IL-36R targets throughout the body and quell the flare. Pharmacokinetic modeling shows that a 900 mg IV dose achieves a peak plasma concentration approximately seven times higher than a 600 mg SC dose.[31] This PK profile aligns perfectly with the clinical outcome observed in the Effisayil™ 1 trial, where a single IV dose led to rapid pustular clearance within one week.[1] In contrast, the goal of maintenance therapy is the long-term prevention of flares, which requires sustained, steady therapeutic drug levels rather than a high initial peak.[33] The SC route, with its slower absorption, lower

Cmax​, and longer Tmax​, provides this exact profile, creating a sustained drug exposure suitable for prophylaxis.[29] This rationale underpins the design of the Effisayil™ 2 prevention trial, which successfully utilized SC maintenance dosing.[34] Therefore, the availability of both IV and SC formulations allows clinicians to deploy Spesolimab strategically: IV for acute rescue and SC for chronic prevention.

3.2 Distribution, Metabolism, and Elimination

• Distribution: Spesolimab exhibits a volume of distribution at steady state (Vss​) of approximately 6.0 to 7.8 L.[29] This value is relatively small, indicating that the drug's distribution is primarily confined to the vascular and interstitial fluid compartments, a typical characteristic for a large protein like a monoclonal antibody.
• Metabolism: As a humanized IgG1 antibody, Spesolimab is not metabolized by hepatic cytochrome P450 enzymes. Instead, it is expected to undergo catabolism through proteolytic degradation into small peptides and individual amino acids, which are then recycled or eliminated by the body. This is the same process by which endogenous immunoglobulins are broken down.[29]
• Kinetics and Elimination: The elimination of Spesolimab follows a pattern known as target-mediated drug disposition (TMDD).[29] At very low, sub-therapeutic concentrations (<0.3 mg/kg), a significant portion of the drug's clearance occurs through its binding to the IL-36R target, resulting in non-linear pharmacokinetics.[29] However, at the clinically relevant doses used for treating GPP (e.g., 900 mg IV), the IL-36R targets become saturated. Once saturated, this specific clearance pathway no longer significantly contributes to overall elimination, and the drug's pharmacokinetics become linear and dose-proportional.[29] In this linear range, Spesolimab demonstrates a low systemic clearance of approximately 0.147 to 0.193 L/day and a long terminal elimination half-life ( t1/2​) ranging from 20 to 35 days (approximately 3 to 5 weeks).[29] This extended half-life is a key property that supports the convenient every-4-week dosing interval for subcutaneous maintenance therapy.

3.3 Immunogenicity and Special Populations

• Immunogenicity: The development of anti-drug antibodies (ADAs) is a potential concern for all biologic therapies. In clinical studies with Spesolimab, ADAs were detected in a subset of patients, with one report noting a rate of 46% after at least one dose.[12] However, the clinical impact of these ADAs on the drug's pharmacokinetics and efficacy was generally low. Only in a few instances where subjects developed very high ADA titres was a minimal impact on Spesolimab plasma concentrations observed.[29]
• Special Populations: Pharmacokinetic studies have demonstrated consistency across different ethnic groups. The PK profiles of Spesolimab were found to be comparable between Japanese and non-Japanese healthy subjects, and similar findings were reported in a study of healthy Chinese subjects.[29] These data suggest that dose adjustments based on these specific ethnic backgrounds are not necessary. Data on pediatric and geriatric use are more limited, although the drug is approved for use in adolescents aged 12 and older weighing at least 40 kg.[17]

Table 2: Summary of Key Pharmacokinetic Parameters of Spesolimab (IV and SC)

Parameter	Intravenous (IV) Administration	Subcutaneous (SC) Administration	Clinical Implication
Bioavailability	100% (complete)	~50% - 70% (dose-dependent)	IV route ensures full and immediate drug delivery for acute situations.
Time to Max. Conc. (Tmax​)	Near-instantaneous	~5.5 - 7 days	IV provides rapid onset of action for flares; SC provides gradual absorption for maintenance.
Max. Concentration (Cmax​)	High peak concentration (e.g., ~7.5x higher for 300 mg IV vs. SC) 31	Lower, flatter peak concentration	High IV peak is ideal for rapid receptor saturation during a flare.
Area Under Curve (AUC)	Higher initial exposure	Lower initial exposure, but can be sustained with maintenance dosing	IV provides greater total drug exposure in the critical initial phase of flare treatment.
Terminal Half-Life (t1/2​)	~20 - 35 days (3 - 5 weeks)	~21 - 28 days (3 - 4 weeks)	Long half-life for both routes supports infrequent dosing, especially the every-4-week SC schedule.

Data sourced from.[29]

Section 4: Clinical Efficacy in Generalized Pustular Psoriasis

The clinical development program for Spesolimab, most notably the Effisayil™ trials, has provided robust, high-level evidence establishing its efficacy in both the acute treatment and long-term prevention of GPP flares. This body of evidence was pivotal for its regulatory approvals worldwide.

4.1 Part A: Treatment of Acute GPP Flares (The Effisayil™ 1 Trial)

The Effisayil™ 1 trial (NCT03782792) was a landmark study, representing the first and largest randomized, double-blind, placebo-controlled investigation of a targeted therapy for patients actively experiencing a GPP flare.[6]

Trial Design

This multicenter Phase II trial enrolled 53 adult patients who were presenting with a moderate-to-severe GPP flare. A flare was defined by specific criteria, including a GPPGA total score of ≥3 and pustulation covering at least 5% of body surface area.[26] Patients were randomized in a 2:1 ratio to receive a single 900 mg intravenous dose of Spesolimab (n=35) or a matching placebo (n=18).[14] The primary and key secondary efficacy endpoints were assessed at the end of Week 1, a time point chosen to evaluate the rapidity of the drug's effect.[26] Patients in either group whose symptoms persisted at Day 8 had the option to receive an open-label dose of Spesolimab.[14]

Efficacy Endpoints and Results

• Primary Efficacy Endpoint: The trial's primary objective was to determine the proportion of patients who achieved complete pustular clearance, defined as a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 (no visible pustules), at Week 1.[26]
• Results: The study met its primary endpoint with compelling results. An impressive 54% of patients treated with Spesolimab were free of visible pustules at Week 1. In stark contrast, only 6% (a single patient) in the placebo group achieved this outcome. This represented a statistically significant and clinically meaningful difference of 49 percentage points (95% CI, 21 to 67; p<0.001).[1]
• Key Secondary Efficacy Endpoint: A key secondary endpoint measured overall skin clearance, defined as the proportion of patients achieving a GPPGA total score of 0 or 1 (representing clear or almost clear skin) at Week 1.[26]
• Results: Spesolimab also demonstrated superiority in this measure. 43% of patients in the Spesolimab arm achieved clear or almost clear skin, compared to only 11% in the placebo arm (Difference: 32 percentage points; 95% CI, 0.022 to 0.527; p=0.02).[6]
• Sustained Response and Patient-Reported Outcomes (PROs): The remarkable improvements observed at Week 1 were durable. Follow-up data showed that among patients initially treated with Spesolimab, over 84% had no visible pustules and 81% had clear or almost clear skin at Week 12.[9] The treatment also had a rapid and significant impact on patient well-being. At Week 1, patients in the Spesolimab group reported clinically meaningful improvements in pain (measured by Visual Analogue Scale), fatigue (FACIT-Fatigue), and overall quality of life (Dermatology Life Quality Index - DLQI) compared to those on placebo.[39]

Table 3: Key Efficacy Outcomes of the Effisayil™ 1 Trial (Week 1)

Endpoint	Spesolimab (n=35)	Placebo (n=18)	Treatment Difference (95% CI)	p-value
GPPGA Pustulation Subscore of 0 (No Visible Pustules)	54%	6%	49% (21 to 67)	<0.001
GPPGA Total Score of 0 or 1 (Clear/Almost Clear Skin)	43%	11%	32% (2.2 to 52.7)	0.02

Data sourced from.[6]

4.2 Part B: Prevention of GPP Flares (The Effisayil™ 2 Trial)

Building on the success of Effisayil™ 1, the Effisayil™ 2 trial (NCT04399837) was designed to investigate a different but equally critical question: whether long-term maintenance therapy with Spesolimab could prevent the recurrence of GPP flares.[33]

Trial Design

Effisayil™ 2 was a 48-week, Phase IIb, multicenter, randomized, double-blind, placebo-controlled trial. It enrolled 123 patients, including adolescents (from age 12) and adults, who had a history of GPP but were in a non-flaring state (clear or almost clear skin) at baseline.[34] Participants were randomized (1:1:1:1) to receive one of three different subcutaneous (SC) Spesolimab dosing regimens or placebo for the duration of the study.[33] The high-dose arm, which corresponds to the now-approved maintenance regimen, consisted of a 600 mg SC loading dose followed by 300 mg SC every 4 weeks.[42]

Efficacy Endpoints and Results

• Primary Efficacy Endpoint: The primary endpoint of the trial was the time to the first GPP flare over the 48-week treatment period.[33]
• Results: The trial demonstrated a profound preventative effect. Compared to placebo, the high-dose Spesolimab regimen significantly reduced the risk of experiencing a GPP flare by 84% (Hazard Ratio = 0.16; 95% CI, 0.05 to 0.54; p=0.0005).[2] In a remarkable finding, after Week 4 of treatment, no flares at all were observed in the high-dose Spesolimab group for the remainder of the 48-week study.[2]
• Secondary Outcomes: Beyond flare prevention, maintenance therapy with SC Spesolimab also led to a continuous improvement in patients' baseline skin condition and quality of life.
• Skin Involvement: In the group receiving the approved high-dose regimen, the mean total Body Surface Area (BSA) affected by GPP showed a steady decline, improving from 13.3% at baseline to 10.6% at Week 4, 9.4% at Week 16, and ultimately to 4.5% at Week 48.[46] This indicates that the treatment not only prevents acute events but also controls the chronic, underlying aspects of the disease.
• Quality of Life: Patients treated with Spesolimab experienced rapid and sustained improvements in their quality of life, as measured by the DLQI. A significantly greater proportion of patients in the Spesolimab group achieved a clinically meaningful improvement (≥4-point reduction) in their DLQI score compared to the placebo group, with benefits seen as early as Week 4 and maintained through Week 48.[42]

The combined results of the Effisayil™ 1 and 2 trials demonstrate the dual role of Spesolimab in GPP management. The first trial established its credentials as a potent and rapid rescue therapy for acute flares, while the second proved its efficacy as a highly effective long-term prophylactic agent. This represents a fundamental evolution in the therapeutic approach to GPP. Previously, management was entirely reactive, focused on controlling devastating flares as they occurred, leaving patients in a state of constant anxiety about the next unpredictable event.[2] The evidence from Effisayil™ 2 supports a paradigm shift towards proactive, preventative disease control. Clinicians now have an evidence-based tool to not only treat flares but to prevent them from happening in the first place, offering patients the potential for sustained remission and the ability to regain control over their lives. This dual efficacy was the cornerstone of the FDA's decision to grant Spesolimab an expanded approval for both acute and chronic GPP management.[3]

4.3 Part C: Other Clinical Evidence and Investigational Uses

The evidence base for Spesolimab is further supported by early-phase and real-world data. The initial signal of efficacy came from a Phase I open-label, proof-of-concept study (NCT02978690) involving seven patients with active GPP flares. In this small cohort, a single IV dose of Spesolimab led to 71% of patients achieving clear or almost clear skin by Week 1, providing the foundational evidence to proceed with larger trials.[6] Since its approval, a growing number of real-world case series have been published, corroborating the rapid and profound efficacy of IV Spesolimab in diverse patient populations, including elderly patients and those who have previously failed multiple other systemic therapies.[4]

The successful targeting of the IL-36 pathway in GPP has also spurred interest in the potential role of Spesolimab in other neutrophilic or autoinflammatory conditions. The drug has been formally investigated in clinical trials for Palmoplantar Pustulosis (PPP), Ulcerative Colitis, and Hidradenitis Suppurativa, suggesting that the therapeutic scope for this mechanism of action may extend beyond GPP.[18]

Section 5: Safety, Tolerability, and Risk Management

A comprehensive assessment of any therapeutic agent, particularly a novel biologic, requires a meticulous evaluation of its safety and tolerability profile. Data from the comprehensive clinical development program for Spesolimab provide a clear picture of its associated risks.

5.1 Overview of Adverse Reactions

Across its clinical trials, Spesolimab has been generally well-tolerated.[11] During the acute one-week treatment period in the Effisayil™ 1 trial, the overall incidence of adverse events (AEs) was comparable between the Spesolimab and placebo groups (66% vs. 56%, respectively).[9]

• Most Common Adverse Reactions (IV for GPP Flare): In patients receiving a single intravenous dose for a GPP flare, the most frequently reported AEs (occurring in ≥5% of patients) were asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection (UTI).[1]
• Most Common Adverse Reactions (SC for GPP Prevention): In patients receiving subcutaneous Spesolimab as a maintenance therapy, the most common AEs reported included injection site reactions (erythema, pain, swelling), arthralgia, pruritus, and UTI.[3]

5.2 Serious Adverse Reactions and Warnings

While generally well-tolerated, Spesolimab is associated with several important risks that require careful management and monitoring.

• Infections: As an immunomodulatory agent, Spesolimab may increase the risk of infections.[25] In the first week of the Effisayil™ 1 trial, infections were reported more frequently in the Spesolimab group (14-17%) compared to the placebo group (6%).[6] The majority of these infections were mild to moderate in severity. One serious infection, a UTI, was reported in a subject (3%) in the Spesolimab group, with none in the placebo group.[25]
• Hypersensitivity and Infusion-Related Reactions: These reactions are a key risk. Two cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were reported in GPP patients treated with IV Spesolimab during clinical trials. However, upon subsequent expert adjudication using the formal RegiSCAR scoring system, these cases were assessed as "no DRESS" and "possible DRESS," suggesting the association was not definitive.[11] Nevertheless, due to the potential severity of such reactions, Spesolimab is contraindicated in patients with a known history of severe or life-threatening hypersensitivity to the drug or its excipients.[1] Mild to moderate infusion-related reactions can be managed by stopping the infusion and restarting at a slower rate upon resolution.[52]
• Risk of Tuberculosis (TB): Consistent with the safety profile of many biologic therapies that modulate the immune system, there is a potential risk of reactivating latent tuberculosis. Therefore, all patients must be evaluated for TB infection (both active and latent) prior to initiating treatment with Spesolimab. Treatment is not recommended in patients with active TB, and prophylactic anti-TB therapy should be considered for those with latent TB.[1]
• Neurological Events: During the broader clinical development of Spesolimab for various (and unapproved) indications, three cases of Guillain-Barré Syndrome (GBS) were reported among approximately 750 exposed subjects. While a causal link has not been definitively established, this finding warrants clinical vigilance.[52]

5.3 Risk Management and Monitoring

To mitigate the identified risks, specific risk management strategies are mandated.

• Contraindications: The only absolute contraindication is a history of severe or life-threatening hypersensitivity to Spesolimab or any of its components.[25]
• Pre-treatment Screening: Before starting Spesolimab, clinicians must ensure that any clinically important active infections are fully resolved or adequately treated. All patients must undergo screening for both active and latent TB.[1]
• Vaccinations: To ensure an adequate immune response and to avoid the risks associated with live pathogens in an immunomodulated patient, it is recommended that all age-appropriate vaccinations be completed according to current guidelines prior to starting Spesolimab. The use of live vaccines is not recommended during treatment and for at least 16 weeks following the last dose.[25]

Table 5: Adverse Reactions Reported in Pivotal Clinical Trials (Spesolimab vs. Placebo)

Adverse Reaction	Effisayil™ 1 (IV Flare Treatment - Week 1)	Effisayil™ 2 (SC Prevention - Exposure-Adjusted Rate per 100 Patient-Years)
	Spesolimab (n=35)	Placebo (n=18)
Any Infection	14% - 17%	6%
Urinary Tract Infection (UTI)	≥5%	<5%
Asthenia / Fatigue	≥5%	<5%
Nausea / Vomiting	≥5%	<5%
Headache	≥5%	<5%
Pruritus / Prurigo	≥5%	<5%
Injection Site Reaction	N/A (IV)	N/A (IV)
Arthralgia	<5%	<5%

Data sourced from.[1] N/A = Not Applicable.

Section 6: Regulatory and Administration Guidelines

6.1 Global Regulatory Approvals and Designations

The clinical significance of Spesolimab is reflected in its rapid and widespread regulatory approval across major global markets, often accompanied by special designations that expedite its review and recognize its importance for a rare disease.

• United States (FDA): The FDA granted Spesolimab both Breakthrough Therapy and Orphan Drug designations, acknowledging its potential to provide a substantial improvement over available therapies for a serious condition.[18] The initial Biologics License Application (BLA) received Priority Review.[54] Approval for the treatment of GPP flares in adults was granted in September 2022.[1] Following the positive results of the Effisayil™ 2 trial, the FDA expanded the indication in March 2024 to include the prevention (maintenance treatment) of GPP flares and extended its use to pediatric patients aged 12 years and older who weigh at least 40 kg.[3]
• European Union (EMA): In December 2022, the European Commission granted a conditional marketing authorization for Spesolimab for the treatment and prevention of GPP flares in adults and adolescents from 12 years of age.[8] The "conditional" status was granted because the drug addresses an unmet medical need for a serious disease, and the benefit of its immediate availability was deemed to outweigh the risk of having less comprehensive long-term data than is normally required. As a condition of this approval, the marketing authorization holder, Boehringer Ingelheim, is required to submit further data from ongoing studies to confirm the long-term safety and effectiveness of the medicine.[8]
• Other Regions: Spesolimab has also secured approval in numerous other regions, including Japan, Mainland China, and India, solidifying its position as the first globally recognized, specifically targeted therapy for GPP.[6]

6.2 Dosing and Administration

The approved dosing and administration schedules for Spesolimab are precisely tailored to its two distinct clinical indications—acute flare treatment and chronic flare prevention—a strategy directly informed by the drug's pharmacokinetic properties.

Table 6: Recommended Dosing and Administration for Spesolimab (Spevigo®)

Indication	Patient Population	Route of Administration	Dosage and Schedule	Available Dosage Forms
Treatment of GPP Flares	Adults and pediatric patients ≥12 years of age and weighing ≥40 kg	Intravenous (IV) Infusion	A single dose of 900 mg administered as an IV infusion over 90 minutes. If flare symptoms persist, a second 900 mg dose may be administered one week after the first dose.	Solution for infusion in a vial (e.g., 450 mg/7.5 mL)
Prevention of GPP Flares (Maintenance Therapy)	Adults and pediatric patients ≥12 years of age and weighing ≥40 kg	Subcutaneous (SC) Injection	A loading dose of 600 mg (administered as four 150 mg injections or two 300 mg injections), followed by a maintenance dose of 300 mg every 4 weeks.	Solution for injection in a prefilled syringe (e.g., 150 mg/mL or 300 mg/2 mL)

Data sourced from.[6]

Section 7: Clinical and Therapeutic Context

To fully appreciate the impact of Spesolimab, it must be positioned within the broader therapeutic landscape for GPP. A critical comparative analysis reveals its unique advantages and helps define its role in managing this complex disease.

7.1 Comparison with Other GPP Treatment Modalities

The introduction of Spesolimab has fundamentally altered the standards for GPP management by establishing a new and significantly higher benchmark for efficacy and evidence. It is the first and only therapy to gain regulatory approval for GPP based on the strength of large, robust, randomized, placebo-controlled clinical trials.[10] In contrast, all other systemic therapies—including traditional agents like retinoids, cyclosporine, and methotrexate, as well as other biologics developed for plaque psoriasis—are used off-label for GPP. The evidence supporting their use is derived largely from lower-quality sources such as case reports, small case series, and retrospective studies, which are inherently limited by small sample sizes, lack of control groups, and potential for bias.[5]

The Effisayil™ 1 and 2 trials provide high-level, Level 1 evidence for Spesolimab, demonstrating a degree of efficacy that was previously unattainable. The ability to render 54% of patients with an acute flare completely free of pustules within one week and to reduce the risk of future flares by 84% over a year sets a new standard.[2] This transition from an empirical, often trial-and-error approach to an evidence-based, targeted strategy is the most significant contribution of Spesolimab to the field. Consequently, it is now positioned as a first-line therapy for GPP in treatment guidelines and recommendations from major dermatological societies.[56]

7.2 Role in Specific Patient Subgroups

While Spesolimab has proven highly effective for GPP, emerging evidence suggests that its role may be more nuanced in patients with complex, overlapping psoriatic phenotypes.

Concomitant Plaque Psoriasis (PsO)

Several case reports and series have observed that while IV Spesolimab is exceptionally effective at resolving the pustular component of GPP, its efficacy for the chronic, scaly plaque component in patients with a mixed GPP/PsO phenotype may be suboptimal.[13] In some of these reported cases, patients who had an incomplete response to Spesolimab subsequently achieved significant improvement or resolution of both pustules and plaques after being switched to an IL-17 inhibitor, such as ixekizumab or secukinumab.[13]

This clinical observation points toward a potential dichotomy in the pathogenic drivers of the two disease manifestations. While the IL-36 pathway appears to be the dominant driver of the acute neutrophilic inflammation and pustulation characteristic of GPP, the IL-23/Th17 axis is well-established as the primary driver of the chronic T-cell-mediated inflammation and keratinocyte hyperproliferation that defines classic plaque psoriasis. In a patient with a mixed phenotype, it is plausible that both pathways are pathologically active, but one may be more dominant than the other. The clinical observation that an IL-36R antagonist excels at treating pustules while an IL-17 inhibitor may be superior for treating the accompanying plaques strongly supports this hypothesis of distinct, albeit overlapping, pathogenic mechanisms.

This has critical implications for the future of personalized medicine in psoriatic disease. For a patient presenting with "pure" GPP or a GPP flare with minimal plaque psoriasis, Spesolimab is the clear, evidence-based choice. However, for a patient with severe, established plaque psoriasis who develops a GPP flare, the optimal long-term maintenance strategy might involve an IL-17 or IL-23 inhibitor to control the dominant plaque phenotype, with Spesolimab potentially reserved for the acute rescue of any breakthrough pustular flares. This nuanced approach requires further investigation but is a vital consideration for clinicians tailoring therapy to the individual patient's specific disease presentation.

Table 7: Comparative Overview of GPP Treatment Modalities

Treatment Class / Agent	Mechanism of Action	Key Efficacy Evidence (for GPP)	Speed of Onset	Major Safety/Tolerability Concerns	GPP-Specific Approval Status (US/EU)
Spesolimab (IL-36R Inhibitor)	Blocks the IL-36 receptor, inhibiting the central inflammatory pathway of GPP.	High-level evidence from RCTs (Effisayil™ 1 & 2): 54% pustule-free at Wk 1; 84% flare risk reduction.	Rapid (hours to days for flares).	Infections, hypersensitivity/infusion reactions (incl. rare DRESS), potential for TB reactivation.	Yes, for treatment and prevention of GPP flares.
IL-17 Inhibitors (e.g., Secukinumab, Ixekizumab)	Inhibit IL-17A, a key cytokine in neutrophil recruitment and inflammation.	Evidence from open-label studies and case series; effective in some patients, especially with concomitant PsO.	Rapid (days to weeks).	Infections (esp. mucocutaneous candidiasis), risk of IBD onset/exacerbation, potential for TB reactivation.	No (Approved for plaque psoriasis).
TNF-α Inhibitors (e.g., Infliximab)	Block TNF-α, a broad pro-inflammatory cytokine.	Evidence from case series and retrospective studies; infliximab noted for rapid action.	Rapid (days), especially infliximab.	Serious infections, potential for TB reactivation, heart failure exacerbation, demyelinating disease, paradoxical induction of GPP.	No (Approved for plaque psoriasis).
Systemic Retinoids (Acitretin)	Modulate epidermal differentiation and proliferation; anti-inflammatory effects.	Evidence from retrospective studies and case reports; slow onset.	Slow (weeks to months).	Teratogenicity (absolute contraindication in pregnancy), hyperlipidemia, hepatotoxicity, mucocutaneous dryness.	No.
Cyclosporine	Potent, broad immunosuppressant (calcineurin inhibitor).	Evidence from case reports and retrospective studies; used for rapid control of severe flares.	Rapid (days to weeks).	Nephrotoxicity, hypertension, hyperlipidemia, increased risk of infections and malignancy. Not for long-term use.	No.
Methotrexate	Broad immunosuppressant (folate antagonist).	Limited evidence for GPP specifically; slow onset.	Slow (months).	Hepatotoxicity, myelosuppression, pulmonary fibrosis, teratogenicity.	No.

Data sourced from.[5]

Section 8: Future Directions and Concluding Remarks

8.1 Ongoing Research and Expanded Indications

The profound success of targeting the IL-36 pathway in GPP has logically spurred further investigation into the role of Spesolimab and this mechanism in other diseases characterized by neutrophilic or autoinflammatory features. Clinical trials have been conducted to explore the efficacy of Spesolimab in conditions such as palmoplantar pustulosis (PPP), ulcerative colitis (UC), and hidradenitis suppurativa (HS), signaling a potential expansion of its therapeutic utility beyond GPP.[9] The long-term safety and efficacy in GPP continue to be monitored in open-label extension studies, such as Effisayil™ ON, which will provide invaluable data on the durability of response and the risk profile over many years of treatment.[16]

8.2 Concluding Expert Assessment

Spesolimab (Spevigo®) represents a transformative and rationally designed therapeutic agent that has fundamentally reshaped the management of Generalized Pustular Psoriasis. Its development was a direct result of a sophisticated understanding of the disease's core molecular driver—the interleukin-36 inflammatory axis. As the first-in-class and first specifically approved therapy for GPP, Spesolimab has unequivocally established a new, evidence-based standard of care.

This new standard is supported by an exceptionally robust body of evidence from the pivotal Effisayil™ clinical trial program. These trials have demonstrated not only a rapid and profound efficacy in the treatment of acute, life-threatening flares but also a remarkable ability to prevent their recurrence with long-term maintenance therapy. The drug's targeted mechanism of action, combined with a manageable and generally favorable safety profile, positions it as a clearly superior option to the older, non-specific, and more toxic immunosuppressants that were previously the mainstay of treatment.

While important clinical questions remain, particularly concerning its optimal role in patients with mixed GPP and plaque psoriasis phenotypes, its impact on the management of GPP is undeniable. Spesolimab has successfully shifted the entire treatment paradigm from a reactive, often desperate, management of symptoms to a proactive, evidence-based strategy of long-term disease control. For the first time, it offers patients with this devastating disease the realistic potential for a life free from the constant fear and burden of unpredictable flares.

Works cited

1. FDA approves the first treatment option for generalized pustular psoriasis flares in adults, accessed August 13, 2025, https://www.boehringer-ingelheim.com/us/human-health/skin-and-inflammatory-diseases/gpp/fda-approves-first-treatment-option-generalized-pustular-psoriasis-flares-adults
2. Spesolimab prevented generalized pustular psoriasis flares in ..., accessed August 13, 2025, https://www.boehringer-ingelheim.com/us/human-health/skin-and-inflammatory-diseases/gpp/spesolimab-prevented-generalized-pustular-psoriasis-flares-effisayil-2-trial
3. FDA Expands Approval of SPEVIGO® for Generalized Pustular Psoriasis, accessed August 13, 2025, https://www.psoriasis.org/advance/fda-spevigo-for-pustular-psoriasis/
4. Treatment with spesolimab in patients with generalized pustular ..., accessed August 13, 2025, https://academic.oup.com/ced/advance-article/doi/10.1093/ced/llaf238/8153554
5. Treatment Options and Goals for Patients with Generalized Pustular ..., accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8801408/
6. Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval - Frontiers, accessed August 13, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1359481/full
7. Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval - PubMed Central, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11298804/
8. Spevigo | European Medicines Agency (EMA), accessed August 13, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/spevigo
9. European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares | Boehringer Ingelheim, accessed August 13, 2025, https://www.boehringer-ingelheim.com/human-health/skin-and-inflammatory-diseases/gpp/european-commission-approves-spevigo-spesolimab-generalized-pustular-psoriasis-flares
10. Current management of generalized pustular psoriasis - PubMed, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/36779681/
11. Spesolimab for the Treatment of Generalized Pustular Psoriasis - PMC - PubMed Central, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10789831/
12. Spesolimab, anti-IL36R, GPP, pustular psoriasis | PTT, accessed August 13, 2025, https://www.dovepress.com/therapeutic-potential-of-spesolimab-sbzo-in-the-management-of-generali-peer-reviewed-fulltext-article-PTT
13. Efficacy of Spesolimab in Treating Generalized Pustular Psoriasis ..., accessed August 13, 2025, https://www.dovepress.com/spesolimab-treatment-in-gpp-impact-of-il-36rn-mutations-and-concomitan-peer-reviewed-fulltext-article-CCID
14. Spesolimab - Wikipedia, accessed August 13, 2025, https://en.wikipedia.org/wiki/Spesolimab
15. en.wikipedia.org, accessed August 13, 2025, https://en.wikipedia.org/wiki/Spesolimab#:~:text=Spesolimab%2C%20sold%20under%20the%20brand,via%20injection%20into%20a%20vein.
16. CDSCO approves SPEVIGO® (spesolimab) - the first treatment option for generalized pustular psoriasis flares in adults | Boehringer Ingelheim, accessed August 13, 2025, https://www.boehringer-ingelheim.com/in/cdsco-approves-spevigo-spesolimab-first-treatment-option-generalized-pustular-psoriasis-flares
17. Spesolimab: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 13, 2025, https://go.drugbank.com/drugs/DB15626
18. Spesolimab for the treatment of flares of generalized pustular psoriasis receives U.S. FDA approval - PsOPsA Hub, accessed August 13, 2025, https://psoriasis-hub.com/medical-information/spesolimab-for-the-treatment-of-flares-of-generalized-pustular-psoriasis-receives-u-s-fda-approval
19. Spesolimab-sbzo (SPEVIGO) in Generalized Pustular Psoriasis National Drug Monograph April 2023 | VA.gov, accessed August 13, 2025, https://www.va.gov/formularyadvisor/DOC_PDF/MON_Spesolimab-sbzo_SPEVIGO_in_Generalized_Pustular_Psoriasis_Monograph_Apr_2023.pdf
20. Spesolimab: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed August 13, 2025, https://www.drugs.com/spesolimab.html
21. Spesolimab-sbzo (intravenous route, subcutaneous route) - Side ..., accessed August 13, 2025, https://www.mayoclinic.org/drugs-supplements/spesolimab-sbzo-intravenous-route-subcutaneous-route/description/drg-20538867
22. Spesolimab (Anti-IL-1RL2 / IL-36R) Interleukins antibody | Read Reviews & Product Use Citations - Selleck Chemicals, accessed August 13, 2025, https://www.selleckchem.com/products/spesolimab-anti-il-1rl2-il-36r.html
23. Spesolimab (BI 655130) | Anti-IL-36R Antibody - MedchemExpress.com, accessed August 13, 2025, https://www.medchemexpress.com/spesolimab.html
24. Spesolimab (BI 655130) | CAS 2097104-58-8 | AbMole BioScience, accessed August 13, 2025, https://www.abmole.com/products/spesolimab.html
25. MOA | Spevigo® (spesolimab-sbzo) Injection - Boehringer Ingelheim, accessed August 13, 2025, https://pro.boehringer-ingelheim.com/us/products/spevigo/moa
26. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare | BMJ Open, accessed August 13, 2025, https://bmjopen.bmj.com/content/11/3/e043666
27. CAS 2097104-58-8 Spesolimab - BOC Sciences, accessed August 13, 2025, https://www.bocsci.com/product/spesolimab-cas-2097104-58-8-410075.html
28. go.drugbank.com, accessed August 13, 2025, https://go.drugbank.com/drugs/DB15626#:~:text=Spesolimab%20binds%20to%20the%20IL,activation%20of%20receptor%20signalling%20pathways.&text=A%20population%20pharmacokinetic%20model%20was,and%20patients%20with%20other%20diseases.
29. Assessment of the Pharmacokinetics and Safety of Spesolimab, a ..., accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9734218/
30. Pharmacokinetics, safety, and tolerability of intravenous spesolimab, an anti-interleukin 36 receptor (IL-36R) monoclonal antibody in healthy male subjects - Careers at Boehringer Ingelheim, accessed August 13, 2025, https://careers.boehringer-ingelheim.com/biberach/what-we-do/publications/articles/pharmacokinetics-safety-and-tolerability-of-intravenous-spesolimab-an-anti-interleukin-36-receptor-il-36r-monoclonal-antibody-in-healthy-male-subjects
31. Pharmacokinetic Modeling of Spesolimab Reveals Key Differences Between IV and Subcutaneous Dosing for Generalized Pustular Psoriasis - Dermatology Times, accessed August 13, 2025, https://www.dermatologytimes.com/view/pharmacokinetic-modeling-of-spesolimab-reveals-key-differences-between-iv-and-subcutaneous-dosing-for-generalized-pustular-psoriasis
32. Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study - PubMed, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/39039387
33. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9823166/
34. A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis | ClinicalTrials.gov, accessed August 13, 2025, https://www.clinicaltrials.gov/study/NCT04399837
35. Spesolimab meets key endpoint for GPP flare prevention ..., accessed August 13, 2025, https://www.boehringer-ingelheim.com/human-health/skin-and-inflammatory-diseases/gpp/spesolimab-meets-key-endpoint-gpp-flare-prevention
36. Spevigo® (spesolimab-sbzo) – Expanded indication - Optum Business, accessed August 13, 2025, https://business.optum.com/en/support/professionalrx-resources/clinicalupdate_spevigo_2024-0320.html
37. Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis | ClinicalTrials.gov, accessed August 13, 2025, https://clinicaltrials.gov/study/NCT03782792
38. Trial of spesolimab for generalized pustular psoriasis - Digital ..., accessed August 13, 2025, https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=13029&context=open_access_pubs
39. Spesolimab improves patient- reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 - Avances en PPG, accessed August 13, 2025, https://www.avancesenppg.com/arxius/medinfo/155_1687359020.pdf
40. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study - PubMed, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/37140190/
41. Spesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): A Video Summary of the EFFISAYIL® 2 Study, accessed August 13, 2025, https://www.biomedicine.video/rare-diseases/spesolimab-treatment-for-the-prevention-of-flares-in-people-with-generalized-pustular-psoriasis-gpp-a-video-summary-of-the-effisayil-2-study
42. Quality of Life Improved in GPP in Effisayil 2 Trial - Dermatology Times, accessed August 13, 2025, https://www.dermatologytimes.com/view/quality-of-life-improved-in-gpp-in-effisayil-2-trial
43. Efficacy and safety of subcutaneous spesolimab for the prevention of ..., accessed August 13, 2025, https://profiles.wustl.edu/en/publications/efficacy-and-safety-of-subcutaneous-spesolimab-for-the-prevention
44. Spesolimab treatment for the prevention of flares in people with ..., accessed August 13, 2025, https://www.tandfonline.com/doi/full/10.2217/frd-2023-0023
45. Visual Abstract | Efficacy and safety of spesolimab in the prevention of generalized pustular psoriasis flares: Effisayil 2 - PsOPsA Hub, accessed August 13, 2025, https://psoriasis-hub.com/medical-information/efficacy-and-safety-of-spesolimab-in-the-prevention-of-generalized-pustular-psoriasis-flares-effisayil-2
46. Spesolimab decreases generalized pustular psoriasis (GPP) body ..., accessed August 13, 2025, https://skin.dermsquared.com/skin/article/view/3137
47. Study Details | Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis, accessed August 13, 2025, https://clinicaltrials.gov/study/NCT02978690
48. Treatment Outcomes and Management of Generalized Pustular Psoriasis with Spesolimab, accessed August 13, 2025, https://skin.dermsquared.com/skin/article/view/3335
49. Psoriasis Completed Phase 2 Trials for Spesolimab (DB15626) | DrugBank Online, accessed August 13, 2025, https://go.drugbank.com/indications/DBCOND0013339/clinical_trials/DB15626?phase=2&status=completed
50. Spesolimab Completed Phase 2 Trials for Ulcerative Colitis Treatment | DrugBank Online, accessed August 13, 2025, https://go.drugbank.com/drugs/DB15626/clinical_trials?conditions=DBCOND0029012&phase=2&purpose=treatment&status=completed
51. GPP Treatment - FDA Approved | Spevigo® (spesolimab-sbzo) Injection, accessed August 13, 2025, https://pro.boehringer-ingelheim.com/us/products/spevigo/
52. SPEVIGO® (spesolimab-sbzo) injection, for ... - accessdata.fda.gov, accessed August 13, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf
53. GPP Flare Treatment Study Design | Spevigo® (spesolimab-sbzo) Injection, accessed August 13, 2025, https://pro.boehringer-ingelheim.com/us/products/spevigo/study-design/gpp-flare-treatment
54. Spesolimab (SPEVIGO®) approved by FDA - The Antibody Society, accessed August 13, 2025, https://www.antibodysociety.org/antibody-therapeutic/spesolimab-spevigo-approved-by-fda/
55. 761244Orig1s000 - accessdata.fda.gov, accessed August 13, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761244Orig1s000Approv.pdf
56. Pustular Psoriasis Treatment & Management: Pharmacologic ..., accessed August 13, 2025, https://emedicine.medscape.com/article/1108220-treatment
57. Union Register of medicinal products - Public health - European Commission, accessed August 13, 2025, https://ec.europa.eu/health/documents/community-register/html/h1688.htm
58. Pustular psoriasis: Treatment - American Academy of Dermatology, accessed August 13, 2025, https://www.aad.org/public/diseases/psoriasis/treatment/medications/pustular
59. Case study: Spesolimab for the treatment of generalized pustular psoriasis after ineffective response to ixekizumab - PsOPsA Hub, accessed August 13, 2025, https://psoriasis-hub.com/medical-information/case-study-spesolimab-for-the-treatment-of-generalized-pustular-psoriasis-after-ineffective-response-to-ixekizumab
60. Psoriasis clinical guideline - American Academy of Dermatology, accessed August 13, 2025, https://www.aad.org/member/clinical-quality/guidelines/psoriasis
61. Pustular Psoriasis Guidelines - Medscape Reference, accessed August 13, 2025, https://emedicine.medscape.com/article/1108220-guidelines